Clinical Trial: NCT04242199
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Incyte Corporation |
| Information Provided By: | Incyte Corporation |
| Last Update Posted: | 2025-07-14 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
Official Title
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
Conditions
Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma
Intervention / Treatment
- Drug: INCB099280
Other Study ID Numbers
- INCB 99280-112
- 2019-004967-35
- 2019
Start Date (Actual)
2020-09-04
Primary Completion Date (Actual)
2024-08-29
Study Completion Date (Actual)
2024-11-21
Enrollment (Actual)
182
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Incyte Corporation |
| Information Provided By: | Incyte Corporation |
| Last Update Posted: | 2025-07-14 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
Official Title
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
Conditions
Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, HepatoCellular Carcinoma, Esophageal Squamous Cell Carcinoma, Merkel Cell Carcinoma, Small-cell Lung Cancer, Mesothelioma, PD-L1 Amplified Tumor (9p24.1), Nasopharyngeal Carcinoma
Intervention / Treatment
- Drug: INCB099280
Other Study ID Numbers
- INCB 99280-112
- 2019-004967-35
- 2019
Start Date (Actual)
2020-09-04
Primary Completion Date (Actual)
2024-08-29
Study Completion Date (Actual)
2024-11-21
Enrollment (Actual)
182
Study Type
Interventional
Phase
Phase 1